How do you ensure GCP compliance across all sites and CROs in your clinical trial?
We support sponsors and investigational sites in the rigorous implementation of Good Clinical Practice per ICH E6(R3): from GCP training and compliance assessments of ongoing trials through to preparation for regulatory inspections. The most common weak point is not the individual procedure, but oversight of third parties: only when sponsor oversight, the trial master file and training status come together continuously does a trial withstand inspection rather than just the audit day.
Overview
Which GCP challenges arise in clinical trials?
GCP training, audit and inspection readiness along ICH E6(R3)
Last updated: August 2, 2026
ICH E6(R3) (Good Clinical Practice) is the international quality standard for the design, conduct, recording and reporting of clinical trials. Adopted at Step 4 on 6 January 2025, it replaces the R2 version of 2016 and has applied in the EU since 23 July 2025. It requires a risk-proportionate quality approach, a documented quality management system and explicit sponsor oversight when engaging CROs. The points at which trials get stuck in practice:
- Newly engaged investigational sites or CROs implement the GCP requirements of ICH E6(R3) inadequately, without the sponsor being able to demonstrate its oversight obligation over these third parties without gaps.
- Informed consent, source data verification and the trial master file are the recurring weak points in regulatory inspections.
- GCP training status across the study team is inconsistent and not documented end to end, a direct compliance risk under ICH E6(R3).
- Audit and inspection readiness is treated as an event rather than a continuous state maintained over the entire trial duration.
Services
How we support you
GCP Training & Certification
In-house foundational and refresher training per ICH E6(R3) for study teams, investigators and site staff. Deliverable: training certificates per participant and complete training-record documentation for the trial master file.
GCP Compliance Assessment
Systematic assessment of the GCP status of ongoing trials along TMF review, protocol deviation analysis, consent documentation and vendor oversight. Deliverable: prioritized risk report with concrete recommended actions per finding.
How we work together
What it comes down to
ICH E6(R3) (Good Clinical Practice) no longer calls for individual procedures but for an end-to-end system of three strands that have to fit together: protection of participants through informed consent, data integrity through source data verification and a fully maintained trial master file, and the sponsor's oversight of every involved investigational site and every CRO. The R2 revision of 2016 already strengthened sponsor oversight explicitly, and ICH E6(R3), applicable in the EU since 23 July 2025, continues that line: responsibility can be delegated to a CRO, the oversight obligation cannot. Anyone who tries to close one of these strands only in time for the inspection loses it as a bottleneck, usually the TMF, which cannot be repaired retroactively.
This is exactly where we come in. The GCP compliance assessment makes visible at the outset which strand is inspection-critical, before training is rolled out and audit dates are scheduled. This creates the sequence that holds: first the documented training status and demonstrated vendor oversight, then the audit per ICH E6(R3) with prioritized CAPA recommendations, and only after that the mock inspection. This shifts the effort to where corrections are inexpensive, into the ongoing trial rather than into inspection day, on which an open finding can no longer be closed without consequences.
Our approach
Our approach
Step
Result
GCP Status Assessment
Inventory of TMF, consent documentation, training status and vendor oversight against ICH E6(R3).
Compliance Assessment
Prioritized risk report: which findings are inspection-critical and which represent effort.
Training & Re-training
Trained study team with documented certificates and a closed training record in the TMF.
Audit
Sponsor and site findings report per ICH E6(R3) with prioritized CAPA recommendations.
CAPA Implementation
Resolved observations with demonstrated effectiveness, documented for the next inspection.
Inspection Preparation
Mock inspection conducted, open items closed before the regulatory date.
Common pitfalls
Where projects commonly fail
Sponsor oversight of CROs is not demonstrated.
ICH E6(R3) sets out the sponsor's oversight obligation explicitly; without documented oversight activities, responsibility delegated to the CRO does not satisfy an inspection and rebounds on the sponsor.
Informed consent is not renewed after substantial protocol amendments.
GCP requires consent before any trial-specific procedures and re-consenting upon relevant changes. Where it is missing, data subsequently collected from the affected participants are open to challenge.
The trial master file is only completed in time for the inspection.
A TMF that is not maintained continuously and completely cannot be repaired at short notice; missing or backdated documents in particular are a recurring inspection finding.
GCP training status is inconsistent and not documented.
When not every involved team member holds a current, evidenced training status, a gap arises that becomes immediately visible in the audit and the inspection.
Source data verification does not cover what risk-based monitoring requires.
If monitoring is not aligned with the trial's actual risks, critical data points remain unverified while effort is spent on non-critical areas.
Product Development & Regulatory Strategy
Do any of these pitfalls apply to you?
In a first call we assess your situation and say what needs clarifying first in your case. Without obligation, reply usually within one working day.
FAQ
Frequently asked questions
Sources
- ICH E6(R3): Guideline for Good Clinical Practice (primary text, Step 4 of 6 January 2025)
- Entourage source material: expertise page Good Clinical Practice (GCP), Clinical & Medical Affairs
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Latest insights
All insights →Regulations & standards considered
- ICH E6(R3) (Good Clinical Practice)
Related topics
Clinical Monitoring →
Risk-based monitoring as the implementation of ICH E6(R3) at the investigational site
Clinical Project Management →
Trial management and sponsor oversight over CROs and investigational sites
GxP Audits (GMP, GLP, GCP) →
Sponsor and site audits with a findings report per ICH E6(R3)
Inspection Readiness →
Preparation for regulatory GCP inspections by EMA, BfArM, PEI and FDA
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences